Liraglutide, an acylated glucagon-like peptide 1 (GLP-1) receptor agonist with a 97% homology to human GLP-1, is employed for the management of glycaemic control in patients with type 2 diabetes. The gene discussed is GCG; the disease is type 2 diabetes mellitus.